Intellia Therapeutics is a biotechnology business based in the US. Intellia Therapeutics shares (NTLA) are listed on the NASDAQ and all prices are listed in US Dollars. Intellia Therapeutics employs 598 staff and has a trailing 12-month revenue of around $53 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $33.53 |
|---|---|
| 52-week range | $32.44 - $63.12 |
| 50-day moving average | $39.80 |
| 200-day moving average | $39.71 |
| Wall St. target price | $83.71 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-5.42 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $33.53 from 2023-09-21
| 1 week (2023-09-15) | -6.39% |
|---|---|
| 1 month (2023-08-23) | -12.57% |
| 3 months (2023-06-23) | -18.18% |
| 6 months (2023-03-23) | -9.82% |
| 1 year (2022-09-23) | -37.82% |
|---|---|
| 2 years (2021-09-23) | -78.40% |
| 3 years (2020-09-23) | 59.06% |
| 5 years (2018-09-21) | 25.21% |
| Revenue TTM | $53 million |
|---|---|
| Gross profit TTM | $-367,858,000 |
| Return on assets TTM | -23.62% |
| Return on equity TTM | -45.68% |
| Profit margin | 0% |
| Book value | $12.51 |
| Market Capitalization | $3.1 billion |
TTM: trailing 12 months
We're not expecting Intellia Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Intellia Therapeutics's shares have ranged in value from as little as $32.435 up to $63.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intellia Therapeutics's is 1.8361. This would suggest that Intellia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intellia Therapeutics, Inc. , a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.